Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02223182 · ClinicalTrials.gov registry record · Phase 1
Efficacy and Safety of Viaskin Milk in Children With IgE-Mediated Cow's Milk Allergy
A Phase 1 study, sponsored by DBV Technologies.
- Completed
- Registry status
- Phase 1
- Development phase
- 198
- Enrollment target
NCT02223182 is a Phase 1 study that has completed, run by DBV Technologies. The registered enrollment target is 198 participants.
The verdict
NCT02223182, a Phase 1 study, has completed, sponsored by DBV Technologies.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 198 participants
- Enrollment target
Study Summary
The objectives of this study are to evaluate the safety and efficacy of Viaskin Milk after 12 months of epicutaneous immunotherapy (EPIT) treatment, for desensitizing IgE-mediated cow's milk allergic children and to assess the long-term safety and therapeutic benefit with Viaskin Milk.
Interventions
- BIOLOGICAL Viaskin Milk 150 mcg
- BIOLOGICAL Viaskin Milk 300 mcg
- BIOLOGICAL Viaskin Milk 500 mcg
- BIOLOGICAL Viaskin Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 198 participants |
| Start Date | 2014-11 |
| Est. Completion | 2020-12-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02223182
The ClinicalTrials.gov registry entry for NCT02223182 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 198 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is DBV Technologies, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Viaskin Milk 150 mcg is the first listed.
NCT02223182 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02223182 about?
NCT02223182 is a clinical study titled "Efficacy and Safety of Viaskin Milk in Children With IgE-Mediated Cow's Milk Allergy". The objectives of this study are to evaluate the safety and efficacy of Viaskin Milk after 12 months of epicutaneous immunotherapy (EPIT) treatment, for desensitizing IgE-mediated cow's milk allergic children and to assess the long-term safety and therapeutic benefit with Viaskin Milk.
What is the current status of trial NCT02223182?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 198 participants. The study started on 2014-11. Estimated completion is 2020-12-22.
What interventions are being tested in trial NCT02223182?
The interventions under investigation include: Viaskin Milk 150 mcg (BIOLOGICAL), Viaskin Milk 300 mcg (BIOLOGICAL), Viaskin Milk 500 mcg (BIOLOGICAL), Viaskin Placebo (BIOLOGICAL).
Who is sponsoring clinical trial NCT02223182?
This trial is sponsored by DBV Technologies, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.